R ecent preclinical and clinical research has suggested that transplantation of bone marrow-derived mesenchymal stromal cells (MSCs) is a promising new approach for the treatment of heart failure. 1 Although cardiomyogenic differentiation of these cells in vivo is limited, MSCs are able to induce therapeutic benefits by secreting various biological factors that promote repair of the failing myocardium (ie, paracrine effects). In addition, the potential utility of allogeneic MSCs remarkably increases the value of these cells as an important donor cell type for cell therapy. 1 Although immunologically most appropriate, the clinical use of autologous MSCs requires bone marrow aspiration from the patients being treated, prolonged in vitro culture for MSC expansion, and quality control and assurance of MSC products for each treatment, imposing significant logistical, economic, and time constraints. Moreover, MSCs from older patients with comorbidities might undermine therapeutic competencies and reduce the ability to expand in vitro. 2 In response to these issues, the use of allogeneic MSCs has been proposed on account of their immune-modulating ability and their relatively low immunogenic phenotype. 1, 3 Previous reports have shown that injection of allogeneic MSCs, without immunosuppressive treatment, improved cardiac function to the same extent as autologous (syngeneic) MSCs in experimental myocardial infarction (MI) models. [4] [5] [6] Allogeneic
MSCs have already been injected in patients with heart failure, and the safety and feasibility (and preliminary effect) of this treatment has been established. 7, 8 Nevertheless, it has also been reported that the immunesuppressive ability of MSCs observed in in vitro settings is not effective enough for transplanted allogeneic MSCs to establish immune privilege in various disease conditions in vivo. 4, 5, 9, 10 Westrich et al observed that %1% of total injected allogeneic MSCs survived at day 2 after intramyocardial injection (a similar ratio to syngeneic MSCs, calculated from their data) in a rat subacute MI model, whereas most allogeneic, but not syngeneic, MSCs subsequently disappeared by day 7. 4 Huang et al reported that %5% of intramyocardially injected allogeneic or syngeneic MSCs similarly existed in the myocardium at day 7 in a rat model of post-MI heart failure, but only syngeneic MSCs were detectable at day 35. 5 Although these data are based on comparisons of quite narrow ranges of donor cell survival (<5% at the initial points studied), they suggest that allogeneic MSCs can survive for a certain early period after transplantation but are eventually rejected.
We recently reported the therapeutic potential of epicardial placement (ie, not injection) of scaffold-free "MSC sheets," which were produced using temperature-responsive polymercoated culture dishes in a rat ischemic cardiomyopathy model. 11 This cell-delivery method, compared with intramyocardial injection, achieved markedly increased initial retention and survival of MSCs. Of note, most epicardially placed MSCs remained on the heart surface with quite occasional migration into the myocardium. We considered that donor cells settling on the heart surface (a virtual space) could receive less blood perfusion (and thus less immune cell attack) than MSCs injected into the myocardium by intramyocardial injection. It is also possible that the epicardium, which is an epithelial cell monolayer on the heart, may work as a physical barrier between MSC sheets and the host myocardium; therefore, epicardially placed allogeneic MSCs might have reduced or delayed susceptibility to the host immune reaction. This study thus examined rejection and acceptance, immunologic responses, and therapeutic effects of allogeneic MSC sheets placed on the epicardial heart surface in a rat heart failure model.
Methods
All studies were performed with the approval of the institutional ethics committee and the U.K. Home Office. The investigation conforms to the Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals (US National Institutes of Health Publication, 1996). All in vivo and in vitro assessments were carried out in a blinded manner if possible.
Preparation of Rat Bone Marrow-Derived MSCs and Bone Marrow Mononuclear Cells
MSCs were isolated from bone marrow of the tibias and femurs of male Lewis or Fischer 344 rats (100-150 g; Charles River UK, Kent, UK) and expanded, as described previously. 11, 12 MSCs were used at passage 3 or 4. Bone marrow mononuclear cells were also collected from the tibias and femurs of male rats, as described previously. 13 
Flow Cytometry and Differentiation Assay of MSCs
For cell-surface marker characterization using flow cytometry, 1910 6 MSCs were stained with 1:100 dilution of FITCconjugated anti-CD34 (Santa Cruz Biotechnology), CD45 (Chemicon), CD90 (Abcam), major histocompatibility complex (MHC) class II (BD Pharmingen), or Alexa 647-conjugated anti-CD29 (BioLegend) or phycoerythrin-conjugated anti-MHC class I (BD Pharmingen) antibodies. Corresponding isotypematched control antibodies were used for negative controls. Samples were analyzed using the Dako Cyan flow cytometer (Dako Cytomation). For in vitro differentiation assays, MSCs were plated on 24-well plates and subjected to adipogenic or osteogenic differentiation medium, as described previously. 11, 12, 14 Adipogenic differentiation medium was a-minimal essential medium supplemented with 100 lmol/L isobutyl methylxanthine (Sigma-Aldrich), 60 lmol/L indomethacin (Fluka), 1 lg/mL insulin (Sigma-Aldrich), and 0.5 lmol/L hydrocortisone (Sigma-Aldrich), whereas osteogenic differentiation medium was a-minimal essential medium supplemented with 0.1 lmol/L dexamethasone (Sigma-Aldrich), 10 mmol/L b-glycerophosphate (Sigma-Aldrich), and 0.05 mmol/L ascorbic acid (Sigma-Aldrich 
Cardiac Function Measurement
Transthoracic echocardiographic determinations were assessed before treatment (4 weeks after MI) and at 28 days after treatment by the Vevo 770 echocardiography machine (VisualSonics) under 1.5% isoflurane inhalation via a nose cone. 11,13,14 LV ejection fraction was calculated from the data obtained with 2-dimensional tracing. LV end-diastolic and endsystolic dimensions, LV wall thickness, and heart rate were measured with M mode. Transmitral peak E/A flow ratio was determined by spectral Doppler traces. All data were collected from at least 3 to 5 different measurements in a blinded manner. Hemodynamic parameters were measured by using cardiac catheterization (SPR-320 and PVAN3.2; Millar Instruments), as described previously. 11, 13, 14 Briefly, under general anesthesia using 1.5% isoflurane inhalation and mechanical ventilation, the catheter was inserted into the LV cavity through the right common carotid artery. Intra-LV and intra-aortic pressure signals were measured with a transducer and conditioner (MPVS-300; Millar Instruments) and digitally recorded with a data acquisition system (PowerLab 8/30; ADInstruments). All data were collected from at least 5 different measurements in a blinded manner.
Quantitative Assessment of Donor Cell Survival
To quantify the presence of grafted male cells in the female heart, the Y chromosome-specific SRY gene was quantitatively assessed by TaqMan real-time polymerase chain reaction (Prism 7900HT; Applied Biosystems). 11, 13, 14 
Analysis of Gene Expression
Total RNA was extracted from collected cells or from the ventricular walls of rats using the RNeasy Mini Kit (Qiagen) and assessed for myocardial gene expression relevant to immunologic responses and MSC-mediated myocardial repair/regeneration by quantitative reverse transcription polymerase chain reaction (Prism 7900HT, Applied Biosystems) in technical duplicate, as described previously.
11,13
TaqMan primers and probes for rat TIMP1, IGF1, VCAM1, SDF1, HIF1A, MMP2, IL10, FGF2, and VEGF were purchased from Applied Biosystems, whereas those for MHC class I, MHC class II, and TMSB4 were from Sigma-Aldrich. Expression was normalized to ubiquitin C. In the figures, expression relative to that of the sham group is presented.
Enzyme-Linked Immunosorbent Assay for Serum Interleukin 6 Levels
Peripheral blood was collected from rats at day 3 after treatment, and serum was obtained by centrifugation. Serum level of interleukin (IL) 6 was measured by using the Rat IL-6 Quantikine ELISA Kit (R&D Systems) in technical triplicate, according to the manufacturer's instructions.
Histological Analysis
The hearts were harvested, fixed with 4% paraformaldehyde, and frozen in OCT compound using liquid nitrogen. Cryosections were cut and incubated with polyclonal anti-cardiac troponin-T antibody (1:200 dilution; HyTest), biotin-conjugated Griffonia simplicifolia lectin I-isolectin B4 (1:100; Vector Laboratories), monoclonal anti-PECAM1 antibody (1:50; AbD Serotec), monoclonal anti-CD4 and anti-CD8 antibodies (1:100; BD Pharmingen), or monoclonal anti-CD68 antibody (1:200; AbD Serotec), followed by visualization using fluorophore-conjugated secondary antibodies (Life Technologies). Samples were analyzed by fluorescence microscopy (BZ8000; Keyence) with or without nuclear counterstaining using DAPI (4 0 ,6-diamidino-2-phenylindole). For semiquantitative assessments, 10 different fields of the border areas (surrounding the infarct) per heart were randomly selected and assessed. For counting numbers of CD4 + , CD8 + , or CD68 + cells, only positive cells having clear DAPI-positive nuclei localized in the MSC sheets were counted. Another set of sections were stained with 0.1% picrosirius red (Sigma-Aldrich) to semiquantify extracellular collagen deposition using ImageJ analysis software (National Institutes of Health). 11, 13 In addition, for detecting adipogenic and osteogenic differentiation, staining with Oil Red O (SigmaAldrich) and Alizarin red (Sigma-Aldrich) was performed, as described previously.
12,14
Statistical Methods 
Results
We previously published the data showing the efficacy of syngeneic MSC sheet therapy by using a rat model similar to that used in this study 11 ; however, no previously published result is re-reported in this paper.
MSCs From Lewis and Fischer 344 Rats Showed Similar Phenotypes
We first characterized similarities (and differences) of 2 types of donor cells: bone marrow-derived MSCs from Lewis rats (RT1 Figure 1A ), adipogenic and osteogenic differentiation ( Figure 1B and 1C) , and MHC class I and II expression ( Figure 1D ) were all compatible for the 2 types of MSCs. In addition, quantitative polymerase chain reaction showed that expression of reparative factors (VEGF, IGF1, SDF1, and HIF1A), which are proposed to play a role in MSC-mediated myocardial repair, 1, 11 was not statistically different between We evaluated immunologic rejection (or acceptance) of allogeneic MSCs placed on the epicardial heart surface in a quantitative manner in a rat model of post-MI heart failure. At 4 weeks after left coronary artery ligation, female Lewis rats (host) underwent epicardial placement of an MSC sheet composed of the same numbers of male allogeneic (Fischer 344) or male syngeneic (Lewis) MSCs. Quantitative polymerase chain reaction for Y chromosome gene sry demonstrated that donor cell survival was equivalent in the auto and allo groups at day 3 (56.0AE7.2% versus 51.1AE7.6% of the total grafted cell number, respectively) ( Figure 2A ). This comparable donor cell survival between syngeneic and allogeneic MSCs was continuously observed at day 10, whereas day 10 donor cell survival was reduced from day 3 survival in both groups (33.1AE5.1% and 27.2AE4.8% in the auto and allo groups). At day 28, donor cell survival of syngeneic MSCs (auto group) was substantially reduced to 8.9AE1.7%. This cell loss was considered to be independent of allorejection. Of note, at day 28, survival of allogeneic MSCs (allo group) was more extensively decreased; only 0.2AE0.0% of allogeneic MSCs survived at this time point. This amplified donor cell loss was considered to be caused by the immunologic rejection of allogeneic MSCs. These time courses of donor cell survival after epicardial placement were confirmed by immunohistofluorescence studies. It was demonstrated that similar quantities of CMDiI-labeled donor MSCs existed with the same epicardial localization in both allo and auto groups at day 3 ( Figure 2B and 2D). Subsequently, the numbers of CM-DiI-labeled donor cells reduced in both groups by day 28; however, the reduction of donor MSCs in the allo group appeared to be more drastic compared with the auto group ( Figure 2C and 2E). The majority of surviving MSCs remained on the heart surface in both groups, and very few donor MSCs migrated into the myocardium throughout the course studied.
These data suggest that epicardially placed allogeneic MSCs survived to an extent similar to syngeneic MSCs in the early phase after transplantation. In the later phase, even syngeneic MSCs were largely lost (for reasons other than allorejection), but the loss of allogeneic MSCs was more extensive because of the addition of alloimmune rejection.
Allogeneic and Syngeneic MSCs Underwent Similar Differentiation in the Heart
Regarding differentiation of donor MSCs after epicardial placement, immunohistolabeling studies demonstrated that there were no donor cells clearly expressing cardiac troponin-T in either the auto or allo group, suggesting limited occurrence of transdifferentiation of donor MSCs to cardiomyocytes. In addition, we did not observe any donor MSCs differentiated to adipocytes or osteocytes in the cell sheet or in the heart ( Figure 3A and 3B) , supporting safety of transplantation of MSCs into the heart. In contrast, detectable numbers of cells were double-positive for CM-DiI and PECAM1 similarly in both allo and auto groups ( Figure 3C ). This indicates that similar endothelial differentiation of donor Quantitative polymerase chain reaction for the male specific SRY gene showed that donor cell survival was equivalent at days 3 and 10 between the groups but was more extensively reduced in the allo group by day 28. n=5 per group at each point, *P<0.05 vs day 3 data in each corresponding group, ✝ P<0.05 vs day 10 data in each corresponding group. B through E, Immunohistostaining showed that the majority of donor MSCs labeled with CM-DiI were retained at the surface of the left ventricular wall similarly between groups at day 3 after epicardial placement (B and D). Thin ventricular walls represent infarct areas. By day 28, donor cell survival was more extensively reduced in the allo group compared with the auto group (C and E). Scale bar=1 mm. MSC indicates mesenchymal stromal cell; N.S., not significant; TnT, troponin T. MSCs (or fusion with host endothelial cells) occurred in both groups. In addition, host-derived (CM-DiI-negative) endothelial cells migrated into the MSC sheets in both groups, suggesting communication between the MSC sheets and host myocardium.
Allogeneic MSC Sheets Evoked a Low-Level Immunologic Response
We found that, consistent with previous reports, 1, 3 in vitro cultured MSCs showed minimal expression of MHC class II molecules and relatively less expression of MHC class I molecules than unfractionated bone marrow mononuclear cells (Figure 4 ). In addition, immunosuppressive abilities of MSCs in vitro have been reported. 1, 3 Despite these findings, our results for donor cell survival (Figure 2A ) indicated that allogeneic MSCs were rejected in the long term, suggesting that the above properties were not effective enough for allogeneic MSCs to be immunologically privileged in vivo. We characterized local immunologic responses induced by epicardially placed allogeneic MSC sheets. Immunohistostaining demonstrated that the number of CD4 + T cells accumulated in the MSC sheet at days 3 and 10 was increased in the allo group compared with the auto group ( Figures 5A and 6A) . In contrast, the number of CD8 + T cells or CD68 + macrophages accumulated in the MSC sheet was not significantly different between the allo and auto groups (Figures 5B, 5C and 6B, 6C). Quantitative reverse transcription polymerase chain reaction revealed that myocardial expression of IL-6 was upregulated in the allo group compared with the auto group ( Figure 7A ). IL-6 has been reported to be involved in promoting allograft rejection. 15, 16 Serum IL-6 levels, however, were unchanged at the minimum detectable levels between groups ( Figure 7B ). In contrast, there was no statistically significant change in expression of IFNG, CCL2, IL2RA, IL1B, or TNF between the auto and allo groups. In addition, upregulation of NOS2, IDO1, TGFB1, and HGF, which reportedly play a role in MSC-mediated suppression of allogeneic responsiveness, 1, 3 in the MSC sheet groups was not statistically significant compared with the sham group ( Figure 8 ). These data collectively suggest that epicardial placement of allogeneic MSC sheets evoked a local immunologic response, albeit low level; however, such responses, characterized with accumulation of CD4 + cells ( Figure 5A ) and upregulation of IL6 ( Figure 7A ), were mostly eliminated by day 28, corresponding to the observation that allogeneic MSCs had been mostly rejected and disappeared by that time (Figure 2A ). 
Allogeneic MSC Sheets Induced Myocardial Upregulation of Factors Related to Myocardial Repair Comparable to Syngeneic MSC Sheets
We next investigated whether epicardially placed allogeneic MSCs, which settled on the heart surface and survived only in the early phase (although at least until day 10), could contribute to a therapeutic effect for heart failure in comparison with syngeneic MSCs. Because the major mechanism underlying MSC-based therapy is considered to be the paracrine effect, 1, 11 we screened for expression of molecules that potentially play a role in this mechanism by quantitative reverse transcription polymerase chain reaction. The results demonstrated that comparable profiles and degrees of myocardial upregulation of factors relevant to tissue repair, anti-inflammation, and neovascular formation, including TIMP1, IGF1, VCAM1, SDF1A, HIF1A, and MMP2, in the allo and auto groups at day 3 after treatment compared with the sham group ( Figure 9A ). It was also noted that upregulation of these genes was reduced to the baseline (values in the sham group) by day 28 ( Figure 9B ).
Epicardially Placed Allogeneic MSC Sheets Induced Tissue Repair of Chronically Failing Myocardium After MI, Similar to Syngeneic MSC Sheets
We examined whether the above-identified early phase upregulation of paracrine factors correlated to histological repair of the post-MI failing myocardium (paracrine effects). At day 28 after MSC sheet therapy, picrosirius red staining showed that post-MI extracellular collagen deposition was reduced in the peri-infarct viable myocardium in both auto and allo groups compared with the sham group ( Figure 10A and  10C) . Isolectin B4 staining showed that the capillary density in the peri-infarct areas was increased similarly in the auto and allo groups compared with the sham group ( Figure 10B and  10D) . These histological results indicate that both syngeneic and allogeneic MSC sheets were able to similarly induce myocardial repair of the injured myocardium in post-MI heart failure, regardless of the different donor cell survival at day 28 (both <10%) (Figure 2A ).
Epicardial Placement of Allogeneic MSC Sheets Improved Global Cardiac Function to the Same Extent as Syngeneic MSC Sheets
We evaluated overall therapeutic effects of allogeneic MSC sheet therapy by measuring cardiac function and structure, in comparison to syngeneic MSC sheet therapy, in the rat model of post-MI chronic heart failure. All pretreatment data on cardiac function measured by echocardiography (at 4 weeks after MI) were comparable between groups (Table 1) . At day 28 after treatment (8 weeks after MI), echocardiography showed that LV ejection fraction was similarly improved in the auto and allo groups compared with the sham group (Table 1) . LV end-diastolic and end-systolic dimensions had a decreasing trend (although not statistically significant) in the auto and allo groups compared with the sham group (Table 1) . Consistent with these, cardiac catheterization demonstrated that maximum/minimum pressure and maximum and minimum dP/dt in the allo group were all improved to the same extent as in the auto group (Table 2) . Both MSC sheet groups had a tendency toward reduced LV end-diastolic pressure Table 2) . These results confirmed that allogeneic MSC sheet therapy was able to achieve therapeutic effects for post-MI heart failure comparable to syngeneic MSC sheet therapy.
Discussion
This study demonstrated that epicardial placement of allogeneic MSCs in the form of cell sheets achieved early phase donor cell survival equivalent to that of syngeneic MSC sheets (%50% at day 3 and %30% at day 10) in a rat model of post-MI chronic heart failure. Toward day 28, donor cell survival was significantly decreased to <10% even in syngeneic MSCs (independent of immunologic rejection), whereas additional cell loss in allogeneic MSCs (survival rate 0.2%) suggested immunologic rejection of these cells. Despite this rejection, which was underpinned by a lowlevel immunologic response, surviving allogeneic MSCs in the early phase were able to achieve a range and degree of myocardial upregulation of reparative factors equivalent to those of the syngeneic MSCs. Importantly, this was sufficient to accomplish structural repair of the post-MI failing myocardium, including increased neovascular formation and reduced fibrosis, to the same extent as the syngeneic MSC sheet therapy. Consequently, overall therapeutic effects (global cardiac function improvement) were equivalent between allogeneic and syngeneic MSC sheets. These data shed light on the potential of allogeneic MSC sheet therapy as an advanced form of MSC-based therapy for heart failure.
Our results accumulate important information regarding immunologic response after allogeneic MSC transplantation to the heart. To date, all such information has been from studies using intramyocardial injection as the cell delivery method, for which the numbers of retained and surviving donor MSCs at the initial assessment point (days 3 4 and 7 5 ) were notably and similarly small (only ≤5% of the total injected cells) in both allogeneic and syngeneic MSCs. 4, 5 This means that >95% of injected MSCs were lost or died early after transplantation independent of alloimmunologic responses. In contrast, the cell sheet technique achieved much greater early survival of MSCs (>50% at day 3; comparable to the syngeneic MSCs). By examining the fate of such larger numbers of initial surviving donor cells, we were able to conclude with more confidence that allogeneic MSCs could afford to survive in the early phase of transplantation (at least for 10 days) but eventually underwent allorejection. The cell sheet technique offers unique epicardial distribution of donor allogeneic MSCs; in contrast, the cells grafted by intramyocardial injection localize within the myocardium. 14 This difference, however, did not appear to significantly affect the majority of immunologic responses by allogeneic MSCs. There appeared to be substantial communication between MSCs between the sheets and the host myocardium, given our results of migration of host immune cells and endothelial cells into the MSC sheets ( Figures 3C and 5) . We observed that rat MSCs exhibit relatively low expression of MHC molecules in vitro, consistent with the previous results. 1, 3 In addition, even if in vivo upregulation of immunosuppressive factors by MSC sheets was not statistically significant in the whole LV samples (presumably due to dilution of the lesion with healthy tissues), immunomodulating secretion by MSCs in vitro is widely known. Nonetheless, such responses were sufficient to reject most allogeneic MSCs by day 28 (although only 9% of transplanted syngeneic MSCs survived at this stage). Our results highlighted that IL6 was particularly upregulated in the heart after allogeneic MSC sheet placement compared with both syngeneic MSC sheet placement and sham treatment. Given the knowledge that IL-6 plays an important role in promoting allograft rejection by modulating T-cell immunity 15, 16 and our finding that other known factors responsible for immunologic responses were not upregulated, it is likely that IL-6 may have a key role in regulating the acceptance and rejection of allogeneic MSCs in the heart. Dhingra et al demonstrated a role for prostaglandin E2 in the survival of allogeneic MSCs after intramyocardial injection in a rat model of subacute MI. 6 Further studies are needed to fully elucidate the mechanism underlying immunologic responses induced by allogeneic MSCs. It is now widely agreed that the major mechanism by which transplanted MSCs improve function of damaged hearts is the paracrine effect rather than cardiomyogenic differentiation of donor MSCs. 1, 11 We demonstrated that even though donor cell survival was significantly reduced by day 28, allogeneic MSC sheets achieved the paracrine effect, comparable to syngeneic MSC sheets. Donor cell survival at days 3 and 10 after allogeneic MSC sheet placement was equivalent to the syngeneic MSC sheet, which enabled similar introduction of reparative signals in the myocardium, including TIMP1, IGF1, VCAM1, SDF1, and HIF1A, during the early phase after treatment. This early phase upregulation was likely sufficient to induce histological repair of the failing myocardium after MI (ie, improved microvasculature formation and reduced pathological fibrosis). Such structural repair by the paracrine effects would, once established, be persistent for a long time, resulting in long-term improvement (at least for 28 days) of cardiac function. These data validate the potential of allogeneic MSC sheet therapy for the treatment of heart failure. Allogeneic MSCs have been administered to patients with various diseases, including graft-versus-host disease, neurological diseases, acute MI, and heart failure. 3, 17 These clinical trials have shown safety (and preliminary efficacy) of allogeneic MSCs, 3, 7, 8, 17 encouraging further development of this strategy. The practicability of allogeneic MSCs validates development of an MSC bank that will enable an "off-theshelf" supply of quality-controlled, quality-assured, most appropriate MSCs with reduced costs on request (no waiting time for MSC expansion). This will greatly support allogeneic MSC sheet therapy in becoming a widely adopted standard treatment for heart failure. 1, 3, 17 Because the cell sheet technique requires the heart to be exposed, a practical strategy would be to combine allogeneic MSC sheet therapy with routine cardiac surgery such as coronary artery bypass grafting; the addition of cell therapy is known to improve the effect of bypass surgery 18 while lowering the shared costs. That said, how long such therapeutic effects of allogeneic MSCs last is a remaining issue and is controversial in small animal models. Lopez et al showed that intramyocardial injection of allogeneic MSCs improves LV ejection fraction for 32 weeks, 19 whereas Huang et al and Dai et al reported negative LV ejection fraction improvement by intramyocardial injection of allogeneic MSCs at 24 weeks. 5, 20 Further studies are needed, probably in a more appropriate setting for investigating a long-term effect of allogeneic MSC sheets, including large animal models or clinical trials.
In conclusion, our data suggested that epicardial placement of allogeneic MSC sheets was not entirely privileged immunologically, but substantial numbers of allogenic MSCs managed to survive for a certain early period. This resulted in significant improvement of cardiac function through enhanced myocardial repair comparable to the syngeneic MSC sheet without causing complications. Further development of this approach (allogeneic MSC sheet therapy), which has potential to be an established treatment for heart failure, is warranted for clinical application.
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